xRead - Olfactory Disorders (September 2023)

20426984, 2022, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22929, Wiley Online Library on [04/09/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

556

INTERNATIONAL CONSENSUS ON OLFACTION

TABLE IX-4 (Continued)

Clinical end point

Study

Year

LOE Study design Study groups

Conclusions Compared with placebo, no significant benefit was noted on BTS or subjective symptom score baseline, significant improvement was noted Compared with

Mott

1997

3

Cohort

CRS (both polyp and nonpolyp patients) Nasal flunisolide twice daily (n = 45)

Subjective

et al 1403

symptom score (0–3) CCCRC olfactory test Data collection: between week 8 toweek26

Compared with

Subjective

Mastalerz et al 1404

1997

2

RCT

CRS (n = 15) (all with aspirin sensitivity; 9 with polyps) FPNS200 μ g once daily × 4weeks Placebo once daily × 4 weeks

placebo, the FP NS group demonstrated significantly greater improvement in subjective symptom

symptom score (0–3)

Data collection points: week 1, week 2,

score at week 2, week 3, week 4

week 3, week 4

Lildholdt et al 1405

1995

2

RCT

CRSwNP (N = 126) Nasal budesonide

Subjective

Compared with

symptom score

placebo, there was no significant benefit in budesonide groups on subjective symptom score

powder 200 μ g twice daily (n = 40) powder 400 μ g twice daily (n = 46)

Data collection

points: week 4

Nasal budesonide

Placebo (n = 42)

Topical

corticosteroid: irrigation

Huang

2019

2

RCT

CRSwNP and CRSsNP Budesonide nasal irrigation (n = 30) Saline irrigations (n = 30)

VAS (0–10)

Compared with baseline, both groups demonstrated significant improvement Compared with saline, the budesonide irrigation group did not demonstrate significantly greater improvement on VAS placebo, there was no significant benefit in the mometasone group Compared with

et al 1406

Harvey

VAS (0–100) Data collection

2018

2

RCT

CRSwNP and CRSsNP MF nasal irrigation 2 mg and placebo spray once daily (n = 21) Placebo irrigation and MF NS 2 mg once daily (n = 23)

et al 1407

points: month 12

on olfactory VAS score at month 12

(Continues)